OraSure Delays Cash-Flow Breakeven To Second Half Of 2027 While Ebola Purchasing Takes Time
Revenue grew 14%, but delayed product adoption has pushed back management's timetable for ending operating cash burn.
OraSure Technologies, which sells rapid diagnostic tests and biological-sample collection devices, pushed its operating cash-flow breakeven target to the second half of 2027 from entering 2027, Chief Financial Officer Ken McGrath said on Monday's earnings call. Management had looked to Ebola testing demand to replace much of the expected revenue contribution from a delayed molecular self-test, but broader purchasing is taking longer than anticipated.
Ebola Authorization Precedes Broader Purchasing
President and Chief Executive Officer Carrie Eglinton Manner pointed to the Bridge Access Study as a catalyst for regional Ebola orders. Answering a Craig-Hallum analyst on the call, she said: "Quite frankly, I would have expected that already."
Africa CDC and WHO lead the study, with UNITAID support, to evaluate diagnostics for the current outbreak. Its evidence is intended to inform recommendations and country and regional decisions about registering and introducing tests. The study was announced in May, with inclusion in June.
OraSure received FDA emergency authorization for its OraQuick Ebola 2.0 test in July and has filled initial commercial orders. The test detects the four Ebola species known to cause disease in humans, including Bundibugyo, responsible for the current outbreak.
Eglinton Manner said African-led evaluation, registration, purchasing and deployment processes were taking time even during the outbreak. She still expected the adoption catalyst before year-end. OraSure has launched local assembly in Uganda through a partner serving HIV testing needs, with potential to add Ebola products; Nigeria is its next planned market for that localized approach.
Growth Hasn't Ended Cash Burn
OraSure's third-quarter revenue reached $30.9 million, up 14% from a year earlier and approximately 1% from the second quarter. Nevertheless, operations consumed $10.9 million in cash. The company ended the quarter with $148.2 million in cash and cash equivalents and zero debt.
Gross margin improved to 45.2% from 43.5% a year earlier as manufacturing efficiencies improved overhead absorption, partly offset by geographic mix. Research and development spending fell $1.8 million from the previous quarter to $7.6 million, while general and administrative costs declined $2.4 million to $12 million. The operating loss was $13 million, or $10.2 million on an adjusted basis.
Responding to a Stephens analyst, McGrath said reaching breakeven would require manufacturing efficiencies, lower operating spending and portfolio revenue growth together. Cost reductions alone were not the basis of the original plan.
OraSure sells diagnostic products and sample-management solutions to healthcare providers, public health agencies, laboratories, researchers and consumer genetics businesses. Diagnostic revenue rose 16% year over year to $16.8 million; sample-management revenue increased 21% to $12.5 million, helped by commercial customer growth and order timing.
The Molecular Test Remains In Discussions
The original cash-flow plan assumed a meaningful contribution from molecular self-testing. OraSure withdrew its FDA submission in August and is now discussing possible routes to resubmission with the agency.
Eglinton Manner said management was planning for a range of regulatory outcomes: "we're prepared to execute on any of those." The timetable depends on FDA discussions. McGrath said the evolving timing of growth opportunities prompted the more conservative breakeven estimate.
Management expects fourth-quarter revenue of $30 million to $32 million, representing approximately 12% to 20% year-over-year growth. It expects full-year revenue of $119.5 million to $121.5 million, up 3.8% to 5.6%, and anticipates faster revenue growth in 2027 from both the existing business and new products.
Management plans to explain its expected 2027 growth acceleration in more detail on the fourth-quarter earnings call.
Sources
- OraSure Technologies Non-GAAP EPS of -$0.15 beats by $0.03, revenue of $30.9M misses by $0.12M (OSUR:NASDAQ) | Seeking Alpha — seekingalpha.com
- OraSure Announces Third Quarter 2026 Financial Results; — globenewswire.com